FATE
Fate Therapeutics, Inc.
stockNASDAQ
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.11 | 2026-10-23 | +0.47% | 1.786 |
| 1M | 2.30 | 2026-10-01 | -7.83% | 2.408 |
| 3M | 2.45 | 2026-07-31 | -13.47% | 1.664 |
| 6M | 1.53 | 2026-05-01 | +38.56% | 1.951 |
| 1Y | 1.35 | 2025-10-31 | +57.04% | 2.110 |
| 2Y | 2.37 | 2024-10-31 | -10.55% | — |
| 5Y | 57.76 | 2021-11-01 | -96.33% | 1.714 |
Fate Therapeutics, Inc. (NASDAQ:FATE) stock price today is $2.12, and today's volume is 1,064,419. FATE is down 2.304% today. The 30 day average volume is 1.30M. FATE market cap is $254.02M with 119.82M shares outstanding.